Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

CR4 > CR4 pharmacology > Flashcards

CR4 pharmacology Flashcards

1
Q

Indications to the uses of Nitrates

A

All types of Angina, acute angina attack (immediate release), prophylactic treatment (long acting)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

MOA low dose nitrates

A

Reduce preload but causing venous vasodilation (reduces the oxugen demand)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

MOA high dose nitrates

A

Arterial dilation - reduces afterload and increases O2 supply

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what enzyme converts Nitroglycerin to NO2

A

Aldehyde dehydrogenase - this is a problem in asians who do not have this enzyme- they cannot take nirtoglycerin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what enzyme converts NO2 to NO

A

P450 dehydrogenase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Acute AE of nitrates

A

headache, flushing, orthostatic hypotension, dizziness, syncope, REFLEX TACH, paradoxical bradycardia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Chronic AE of nitrates

A

NITRATE TOLERANCE , dependence withdrawl, Methemoglobinemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Nitrate DDI (major)

A

PDE inhibitors (-fils) - can cause major hypotension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Nitrate metabolism

A

high first pass metabolism (cant be taken orally)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Nitrate contraindications

A

Hypotension (SBP <100), elevated intracranial pressure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

PDE inhibitor uses

A

Erectile dysfunction, Pulmonary HTN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MOA PDE inhibitor

A

enhabce the effect of NO on smooth muscle by allowing degradation of cGMP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

PDE inhibitor AE

A

mainly due to vasodilatriy effects, visual disturbances

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

First line drug for stable angina

A

Beta blocker

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

First line drug for unstable angina

A

Beta blocker

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

First line drug for the prevention/decreasing frequencty of anginal attacks

A

Beta blocker- has survival benefits

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

drug for exercise induced angina

A

Beta Blocker (remember a side effect is exercise intolerance)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

which BB have vasodilatory effects, what are these effects

A

Lebetilol and Cavedilol - block alpha receptors by reducing IP3 generation in vascular smooth muscle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Which BB have intrisic sympathomemetic activity, what are these effects

A

Pindolol, Acebutolol - partial B1 and B2 agonists (enough stimulation that they are tolerable)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Which BB has B3 receptor agonist activity

A

Nebivolol - enchances NO production (may relieve erectile dysfunction)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

BB major DDI

A

Insulin, hyperglycemic agents, verapamil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Lipid soluble BB metabolism

A

Propranolol and Metoprolol are metabolized by the liver (CYP2D6)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Hydrophilic BB metabolism

A

Nadalol and atenolol - renal excretion unchanged

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

discontinuation of BB

A

over 2 week period to prevent refelex vasoconstriction that can worsen cardiac ischemia - can be mitigated by using a CaBlocker (dihydropyradine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

BB are contraindicated in what form of angina

A

Varient (Prinzmetal) - can potentiate vasoconstriction as a result of unopposed alpha adrenergic activity in coronary smooth muscle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

BB Contraindications

A

variant angina, asthma, raynauds, AV block, Bradycardia, depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Indications for the use of calcium channel blockers

A

1: Stable or variant angina 2: Can prevent angina but do not have the survival benefits that beta blockers do - used as a monotherapy when BB are contraindicated 3: Add on therapy to BB when theraputic goals are not being met (Dihdyrdopydradines) **THIS IS MORE EFFECTIVE THAN USING EACH DRUG ALONE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Non-dihydropyridines MOA

A

Dilt and Verapamil - Reduce voltage dependent L-type calcium channels in cardiac muscle - slow conduction through AV node (prevents Ca channel recovery) - decreased contractility due to decrease in calcium - relax nonvascular smooth muscle (Bronchial, GI, Uterine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Dihydropyridine MOA

A

Pines - reduce voltage gated L-type calcium in smooth musle cells. effective vasodilatirs therfore decrease PR and BP (afterload)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Calcium channel blocker AE

A

Short acting result in HYPOTENSION, REFLEX TACH, RISK OF MI, peripheral edema, headache, flushing, nausea . Long term results in PERIPHERAL EDEMA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Non-dihydropyridines DDI

A

Beta blockers (can induce severe Bradycardia) , increase [Digoxin]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Dihydropyridine DDI

A

These drugs do not produced DDI because they are not block or induce CYP34A - other drugs can affect the concentrtaion of dihydropyradines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Non-dihydropyridines Metabolism

A

CYP3A4, block p-glycoprotein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Dihydropyridine Metabolism

A

CYP3A4

35
Q

Non-dihydropyridine Contraindications

A

HF, AV conduction problems, Sick Sinus Syndrome, Hypotension, Aortic Stenosis

36
Q

Dihydropyridine contraindications

A

Hyptension, aortic stenosis

37
Q

Indication for use of Ranolazine

A

Stable angina as an add on agent if preventative goals have not been achieved. Combination therapy with nitrates, BB, or dihydropyradines. Can be used as BB alternative in contraindications and AE

38
Q

Ranolazine MOA

A

blocks cardiac late Na channels - revereses the effect of Na buidup that occurs in ischemia and assures NCX goes in the correct direction (Na in Ca out)

39
Q

Ranolazine AE

A

Long QT syndrome (due to block of Ikr)

40
Q

Ranolazine DDI

A

Verapamil and Diltiazem, Ketoconazole (CYP34a blockers), Inhibits metabolism of digoxin and simvastatin (dose adjust these drugs)

41
Q

in addition to anginal tretemt all patients should begin …

A

1: Antiplatelet (Asprin) 2: Antihypertensive (Atorvastatin)

42
Q

what classes are used in unstable angina

A

Beta blockers and nitrates

43
Q

What classes are used in variant angina

A

Nitrtes and Calcium channel blockers

44
Q

ACE-I MOA

A

suppress RAAS systme – reduced preload and afterload (relaxation og blood vessels, reduce fluid and sodium retention) and inhibit remodeling

45
Q

First choice treatment for CHF

A

ACE - used in all patients with HFrEF (reduces mortality up to 6 months)

46
Q

ACE -I AE

A

GI, headache, dizziness, hypotension, HYPERKALEMIA, hypoglycemia, renal function impairment, ANGIOEDEMA, **COUGH

47
Q

ACE-I CI

A

Pregnancy, bilateral renal stenosis - less effective in black population

48
Q

Clinical use of ARB

A

used as an alternative only in patients who cannot tolerate ACE

49
Q

Patient presents with NYHA II and EF 30%. Current medications include an ace and an a beta blokcer. The patinet remains symptomatic. What drug do you give to reduce mortality and cardiac remodeling

A

Aldosterone receptor antagonist (Spiralactone eperenone)

50
Q

Patinet has syptoms of HF and LVEF < 40% with a history of diabetes what drug would you give

A

Aldosterone receptor antagonist (Spiralactone eperenone)

51
Q

Aldosterone receptor antagonits major AE

A

HYPERKALEMIA, ACIDOSIS , gynecomatasia

52
Q

Aldosterone receptor antagonist DDI

A

Oral K, other K sparing diuretics, NSAIDS

53
Q

Aldosterone receptor antagonist CI

A

Renal isnufficiency, Serum K >5

54
Q

BB MOA

A

reduced workload of the heart, decreased HR and contractility. Prevent RAAS activation- prevent fluid retention and remodeling. Reduce cardiac remodeling and mortality

55
Q

BB Indication

A

Anyone with HFrEF on standard thearpy (ACE and diuretic as needed) who are hemodynamically stable (NO HYPOTENSION)

56
Q

BB AE

A

Bradycardia (decreased HR), reduced exercise tolerance, fluid retention, worsening HF, hypotension

57
Q

BB DDI

A

Digoxin

58
Q

BB CI

A

Unstable HF, severe bradycardia, and heart block. Carvedilol should not be used in patients with asthma and COPD

59
Q

Which drug can replace ACE in patient who can tolerate ARBs and are NYHA II or III

A

ARNI (sacubitril and valsartan: further reduce morbidity and mortality) Enhance the action of NP and supress the effect of Ang II

60
Q

ARNI AE

A

Hypotension, Hyperkalemia, renal impairment

61
Q

ARNI DDI

A

RAAS inhibitors

62
Q

ARNI CI

A

pregnancy, bilateral renal stenosis , HX OF ANGIOEDEMA

63
Q

47 year old african american female (ACE/ARB intoleranct) presents with NYHA III HFrEF who is symptomatic on standard therapy. What durg should be given

A

Hyrdralazine+ Isorbide (arteial and venous dilators)

64
Q

Vasodilator CI

A

PDE inhibitors and Hypotension

65
Q

Most common side effect of vasodilators

A

Flushing - also cause headache, postural hypotension, reflex tach, fluid retention and LUPUS ERYTHEMATOSUS LIKE SYNDROME

66
Q

Loop diretic MOA

A

Relive pulmonary and peripheral congestion by inhibiting Na/K/2Cl in the thick ascending limb of the loop of henle and promoting renal loss of sodium and water

67
Q

First line for rapid relief of congestion symptoms in HF

A

Loop Diuretic

68
Q

Major AE of Loop Diuretics

A

Alkalosis, HYPOKALEMIA , Dilutional hyponatremia, ** Ototoxicity

69
Q

Digoxin MOA

A

ionotropic drug. Inhibits Na/K ATPase – slows down the NaCa exchange thereby increasing the amount of Ca in the cell - increases contractility. At theraputic doses it slows HR and increases Contractility

70
Q

Patient presents with symptomatic HFrEF. They are currently taking ACE, BB, aldosterone receptor blocker, and diuretic. What drug do you give

A

Digoxin

71
Q

Patient presents with CHF and atrial fibrillation - what drug do you give

A

Digoxin

72
Q

Patient complains of bludrred vision,altered color perception and hallows around dark objects- what drug are they taking

A

Digoxin

73
Q

Digoxin DDI

A

Diuretics, CCB, BB

74
Q

Patient is experiencing Digoxin toxicity - how do you treat

A

Lower or discontinue digoxin, correct electrolyte abnormalities (Mg, K) treat arrythmia with antiarrythmic, and give Digibind to reverse toxicity

75
Q

Beta adrenergic receptors used in heart failure

A

Dopamine and dobutamine

76
Q

Dopamine and dobutamine MOA

A

Ionotropic agent. Bind to B1 receptor and increase CAMP and PKA to promote Ca release to increase cardiac contractility

77
Q

Dopamine and dobutamine indication

A

short term for treating end stage heart failure - patients with systolic dysfunction who don’t respond to other therapies and have organ hypoperfusion. Also increases contractility in acute HF

78
Q

dopamine and dobutamine AE

A

tachycardia and Arrythmia (due to increased Ca)

79
Q

PDE inhibitors

A

Milrinone and Imamirone

80
Q

what drugs are indicated in end stage heart failure

A

PDE inhibitors and Vasodilators (dopamine and dobutamine)

81
Q

PDE inhibior indication

A

Shor term use in treating end stage heart failure- systolic dysfunction who don’t respond to other therapies and have end organ hypoprofusion

82
Q

Ivabradine MOA

A

Slows HR by blocking the cardica pacemaker If current (funny channel)

83
Q

Ivabradine Indication

A

Worsening HF in patients with stable symptomatic HF, LVEF <35% who are in sinus whythm with a resting HR >70 bpm and who are on maximum tolerated doses of BB or have a contraindication to BB

CR4 (7 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions